Show simple item record

dc.contributor.authorKarch, André
dc.contributor.authorSchindler, Daniela
dc.contributor.authorKühn-Steven, Andrea
dc.contributor.authorBlaser, Rainer
dc.contributor.authorKuhn, Klaus A
dc.contributor.authorSandmann, Lisa
dc.contributor.authorSommerer, Claudia
dc.contributor.authorGuba, Markus
dc.contributor.authorHeemann, Uwe
dc.contributor.authorStrohäker, Jens
dc.contributor.authorGlöckner, Stephan
dc.contributor.authorMikolajczyk, Rafael
dc.contributor.authorBusch, Dirk H
dc.contributor.authorSchulz, Thomas F
dc.date.accessioned2021-02-11T15:18:22Z
dc.date.available2021-02-11T15:18:22Z
dc.date.issued2021-01-25
dc.identifier.citationEur J Epidemiol. 2021 Jan 25. doi: 10.1007/s10654-020-00715-3. Epub ahead of print.en_US
dc.identifier.pmid33492549
dc.identifier.doi10.1007/s10654-020-00715-3
dc.identifier.urihttp://hdl.handle.net/10033/622734
dc.description.abstractInfectious complications are the major cause of morbidity and mortality after solid organ and stem cell transplantation. To better understand host and environmental factors associated with an increased risk of infection as well as the effect of infections on function and survival of transplanted organs, we established the DZIF Transplant Cohort, a multicentre prospective cohort study within the organizational structure of the German Center for Infection Research. At time of transplantation, heart-, kidney-, lung-, liver-, pancreas- and hematopoetic stem cell- transplanted patients are enrolled into the study. Follow-up visits are scheduled at 3, 6, 9, 12 months after transplantation, and annually thereafter; extracurricular visits are conducted in case of infectious complications. Comprehensive standard operating procedures, web-based data collection and monitoring tools as well as a state of the art biobanking concept for blood, purified PBMCs, urine, and faeces samples ensure high quality of data and biosample collection. By collecting detailed information on immunosuppressive medication, infectious complications, type of infectious agent and therapy, as well as by providing corresponding biosamples, the cohort will establish the foundation for a broad spectrum of studies in the field of infectious diseases and transplant medicine. By January 2020, baseline data and biosamples of about 1400 patients have been collected. We plan to recruit 3500 patients by 2023, and continue follow-up visits and the documentation of infectious events at least until 2025. Information about the DZIF Transplant Cohort is available at https://www.dzif.de/en/working-group/transplant-cohort .en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectClinical cohort studyen_US
dc.subjectImmunosuppressionen_US
dc.subjectInfectionen_US
dc.subjectOrgan transplantationen_US
dc.titleThe transplant cohort of the German center for infection research (DZIF Tx-Cohort): study design and baseline characteristics.en_US
dc.typeArticleen_US
dc.identifier.eissn1573-7284
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalEuropean journal of epidemiologyen_US
refterms.dateFOA2021-02-11T15:18:24Z
dc.source.journaltitleEuropean journal of epidemiology
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Karch et al.pdf
Size:
809.3Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International